Upcoming Annual General Meeting of Genmab A/S
Company Announcement
Genmab A/S is set to hold its Annual General Meeting on March 12, 2025.
Genmab A/S (Nasdaq: GMAB) will convene its Annual General Meeting at 2:00 PM CET at a designated venue in Copenhagen. This meeting presents a significant opportunity for shareholders and stakeholders to engage with the company’s future plans and strategies.
The official notice for the Annual General Meeting will include essential documents such as the candidates up for election to the Board of Directors and proposed changes to the Remuneration Policy.
Genmab's Mission and Vision
Learn about Genmab's commitment to patients
As a pioneering biotechnology company, Genmab A/S focuses on delivering innovative therapies that have the potential to change patients' lives. With an extensive history spanning over 25 years, the company has developed cutting-edge antibody technology that underscores its commitment to advancements in healthcare.
Genmab aims to achieve its ambitious vision by 2030, which encompasses creating transformative antibody solutions for patients suffering from cancer and other serious diseases. Its powerful pipeline features various innovative products, including bispecific T-cell engagers and next-generation immune checkpoint modulators.
Company Overview
About Genmab
Founded in 1999 and headquartered in Copenhagen, Denmark, Genmab operates with a robust international presence across North America, Europe, and Asia Pacific. The company’s diverse and dedicated team strives tirelessly to enhance the quality of life for patients through revolutionary treatments.
With an unwavering commitment to research and development, Genmab has positioned itself at the forefront of antibody therapeutics. The company emphasizes collaboration and innovation, which allows it to maintain a competitive edge in the rapidly evolving biotechnology landscape.
Stay Connected with Genmab
Follow Genmab for updates and insights
To stay informed about Genmab’s latest developments, interested parties can visit their website, Genmab.com, where detailed information on their projects and announcements can be found. Additionally, following Genmab on social media platforms like LinkedIn and X provides further insights into their journey and corporate updates.
Contact:For more inquiries, contact:
Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs
T: +1 609 524 0065; E: mmp@genmab.com
Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558; E: acn@genmab.com
Frequently Asked Questions
What is the purpose of the Annual General Meeting for Genmab?
The Annual General Meeting allows shareholders to engage with the company's management, review essential proposals, and cast votes on key decisions.
When will Genmab's Annual General Meeting take place?
The meeting is scheduled for March 12, 2025, at 2:00 PM CET.
Where is Genmab’s Annual General Meeting being held?
It will be held at a venue in Copenhagen, details of which will be provided in the official notice.
What important documents are available for the Annual General Meeting?
The notice will include candidates for the Board of Directors and proposed amendments to the Remuneration Policy.
How can I stay informed about Genmab’s updates?
You can visit Genmab’s official website or follow them on social media platforms for regular updates and insights.
